Substratum Stiffness and Latrunculin B Regulate Matrix Gene and Protein Expression in Human Trabecular Meshwork Cells

Sara M. Thomasy,1,2 Joshua A. Wood,1,2 Philip H. Kass,3 Christopher J. Murphy,1,4 and Paul Russell1

PURPOSE. To determine the impact of substratum stiffness and latrunculin-B (Lat-B), on the expression of several matrix proteins that are associated with glaucoma.

METHODS. Human trabecular meshwork (HTM) cells were cultured on hydrogels possessing stiffness values mimicking those found in normal (5 kPa) and glaucomatous meshworks (75 kPa), or tissue culture polystyrene (TCP, >1 GPa). Cells were treated with 2.0 μM Lat-B in dimethyl sulfoxide (DMSO) or DMSO alone. RT-PCR was used to determine the impact of substratum stiffness and/or Lat-B treatment on the expression of secreted protein, acidic, cysteine rich (SPARC), myocilin, angiopoietin-like factor (ANGPTL)-7, and transglutaminase (TGM)-2. Immunofluorescence was used to assess changes in protein expression.

RESULTS. SPARC and myocilin mRNA expression were dramatically increased on the 75 kPa hydrogels and decreased on the 5 kPa hydrogels in comparison to TCP. In contrast, ANGPTL-7 mRNA and TGM-2 mRNA was decreased on the 75 kPa and 5 kPa hydrogels, respectively, in comparison with TCP. Treatment with Lat-B dramatically downregulated both SPARC and myocilin on 75 kPa hydrogels. In contrast, cells grown on TCP produced greater or similar amounts of SPARC and myocilin mRNA after Lat-B treatment. SPARC and myocilin protein expression paralleled changes in mRNA expression.

CONCLUSIONS. Substratum stiffness impacts HTM matrix gene and protein expression and modulates the impact of Lat-B treatment on the expression of these matrix proteins. Integrating the use of biologically relevant substratum stiffness in the conduction of in vitro experiments gives important insights into HTM cell response to drugs that may more accurately predict responses observed in vivo. (Invest Ophthalmol Vis Sci. 2012;53:952–958) DOI:10.1167/iovs.11-8526

Glaucoma is a common cause of blindness worldwide and is associated with irreversible degeneration of the optic nerve head. Although the mechanisms contributing to the onset of most glaucomas are multifactorial, a primary risk factor is increased intraocular pressure (IOP).1 IOP is likely elevated because of an abnormal increase in resistance to aqueous outflow in the human trabecular meshwork (HTM).1–3

The HTM is an intricate, three-dimensional structure comprised of extracellular matrix (ECM) possessing intrinsic complex topography and stiffness that supports the overlying trabecular meshwork cells. Many ECM proteins have been implicated in glaucoma including myocilin, transglutaminase (TGM)-2, fibronectin, and angiopoietin-like factor (ANGPTL)-7.4–5

HTM cells are provided with thousands of biophysical cues through cell-cell interactions, cell-ECM interactions, and fluctuations in IOP. It has been previously demonstrated that nano- to submicron scale topography with features similar to native ECMs and basement membranes dramatically altered HTM cell behavior and expression of the ECM proteins, myocilin and versican.6 Mechanically stretching HTM cells, which occurs with increased IOP, has also been shown to upregulate more than 100 genes including secreted protein, acidic, cysteine rich (SPARC), fibronectin, and myocilin.7,8 In situ, HTM cells are exposed to dynamic, compliant substrates that markedly differ from flat, rigid substrates such as glass or tissue culture polystyrene (TCP) which are typically used in laboratory investigations of HTM cellular behavior. A recent study demonstrated that the HTM elastic modulus, a measure of stiffness, is markedly increased in the glaucomatous HTM.9 Substratum elastic modulus has been shown to modulate a variety of fundamental cell behaviors.9–13 Hydrogels mimicking the elastic modulus of normal and glaucomatous HTM have been shown to dramatically alter cytoskeletal structure and dynamics, protein expression patterns, cell stiffness, cell behavior, and the cellular response to therapeutic agents such as latrunculin-B (Lat-B).2,14–15

Lat-B is an actin cytoskeleton disruptor that is currently in human clinical trials as a novel glaucoma treatment directed specifically at the trabecular meshwork. The only clinically validated treatments for glaucoma act by lowering IOP by decreasing aqueous humor (AH) production or by decreasing the resistance to AH outflow. With the exception of Lat-B and Rho-kinase inhibitors, these therapeutic approaches do not target the HTM.16 Lat-B is thought to decrease IOP by decreasing the resistance to AH outflow through the HTM.17–21 Recently, it has been demonstrated that HTM cells adhered to stiffer substrates were significantly more responsive to Lat-B due to the increased number of actin stress fibers suggesting that the effects of Lat-B treatment would be most pronounced in glaucomatous eyes with a stiffer HTM.2 In addition, Lat-B treatment significantly diminished HTM cell migration on stiffer substrates.15 However, the effect of substratum stiffness on the expression of ECM proteins before and after Lat-B
exposure has not been reported. The purpose of this investigation was to determine the impact of Lat-B treatment in the context of substratum stiffness on the expression of several ECM proteins, myocilin, SPARC, ANGPTL-7, fibronectin, and TGM-2 that have been implicated in glaucoma.1,2,23 A better understanding of the impact that clinically relevant substratum stiffness has on ECM gene and protein expression will inform the design of improved in vitro testing methodologies especially with regard to identification and development of novel glaucoma therapeutics.

METHODS

Hydrogel Fabrication
Polycrylamide hydrogels that mimic the stiffness of the normal (5 kPa) and glaucomatous (75 kPa) HTM as well as an intermediate stiffness (25 kPa) were prepared as previously described.2,9 All experiments complied with the tenets of Declaration of Helsinki. Isolated cells were cultured in DME/F-12 medium containing 2.5 mM glutamine supplemented with 10% fetal bovine serum (Atlanta Biologicals, Lawrence, GA) and 1% penicillin-streptomycin with amphotericin B (Lonza, Walkerville, MD). All studies were conducted using cells before the eighth passage. HTM cells were plated at a density of 1.5 × 10^5 on FNC-coated 5 kPa hydrogels and 2.5 × 10^5 on FNC-coated TCP, 25 and 75 kPa hydrogels for 24 hours before Lat-B treatment. The 5 kPa hydrogels were plated at a higher density than the other substrates because HTM cells proliferate more slowly on the 5 kPa hydrogels.15

Latrunculin-B Treatment
Lyophilized Lat-B (Cal Biochem, La Jolla, CA) was resuspended to a final concentration of 2.5 mM in dimethyl sulfoxide (DMSO) (Fisher, Pittsburgh, PA). Fresh solutions of 2.0 μM Lat-B were prepared in serum-free DPBS for all experiments. Control samples were treated with an equivalent concentration of DMSO in serum free DPBS. Treatment with DMSO was compared with serum free DPBS only to ensure DMSO did not have an additional effect on HTM cells. After a 30-minute treatment in Lat-B or vehicle (DMSO), cells were rinsed twice with DPBS wash, the cells were permeabilized with 0.1% Triton X-100 in 10% Superblock at 4°C for 12 hours. Cells were washed twice with 10% Superblock before incubation with Alexa 488-conjugated donkey anti-rabbit antibody (Abcam, San Francisco, CA) or 1:10 chicken anti-myocilin antibody in 10% Superblock at 4°C for 12 hours. Cells were washed twice with 10% Superblock before incubation with Alexa 488-conjugated donkey anti-rabbit antibody or Alexa 488-conjugated goat anti-chicken antibody in 10% Superblock at room temperature in the dark for 1 hour. Cells were washed twice with 10% Superblock and cell nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI) (Invitrogen, Carlsbad, CA). After a DPBS wash, cells were left in 1 mL of DPBS until immunofluorescent imaging with an upright microscope (Zeiss Axio Scope.A1; Carl Zeiss Inc., Thornwood, NY) with a camera (AxioCam HRc; Carl Zeiss Inc.). For analysis of SPARC protein expression, images were obtained from each substrate and treatment at the same exposure time of 3.0 seconds using the 10 × air objective for Alexa 488 fluorescence. For analysis of myocilin protein expression, images were obtained from each substrate and treatment at the same exposure time of 1.0 second using the 10 × air objective for Alexa 488 fluorescence. A negative control was performed for each substrate and treatment which did not contain any primary antibody.

Statistical Analysis
Data were analyzed using a software package (Sigma Plot 11; Systat Software, Chicago, IL). A one-way repeated measures analysis of variance (RMANOVA) was used to assess the effect of compliance on the expression of ANGPTL-7, TGM-2, and fibronectin with or without Lat-B treatment. If the one-way RMANOVA was significant, Student’s t-tests were performed with a sequentially rejective adaptation of the Bonferroni correction for multiple comparisons to compare each compliant hydrogel with other compliant hydrogels or TCP with or without Lat-B treatment. A two-way RMANOVA was used to assess the effects of
compliance and donor on the expression of SPARC and myocilin. If the two-way RMANOVA was significant, Student’s t-tests were performed with a sequentially rejective adaptation of the Bonferroni correction for multiple comparisons to compare each compliant hydrogel with other compliant hydrogels or TCP with or without Lat-B treatment. A Student’s t-test was used to compare the effect of Lat-B versus DMSO treatment for each compliance. Significance was set at \( P < 0.05 \) for all analyses. All data are presented as mean ± SEM.

**RESULTS**

**Substratum Stiffness and Lat-B Alters SPARC and Myocilin Expression**

Substratum stiffness by itself dramatically altered the relative amount of both SPARC and myocilin mRNA (Table 1, Figs. 1, 2).

<table>
<thead>
<tr>
<th>SPARC</th>
<th>DMSO</th>
<th>Lat-B</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 kPa</td>
<td>0.74 ± 0.08a</td>
<td>0.45 ± 0.05as</td>
</tr>
<tr>
<td>25 kPa</td>
<td>4.7 ± 1.7</td>
<td>1.3 ± 0.07bs</td>
</tr>
<tr>
<td>75 kPa</td>
<td>2.7 ± 0.45b</td>
<td>0.85 ± 0.10†</td>
</tr>
<tr>
<td>TCP (&gt;1 GPa)</td>
<td>1.0</td>
<td>0.9 ± 0.03</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Myocilin</th>
<th>DMSO</th>
<th>Lat-B</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 kPa</td>
<td>1.7 ± 0.15as</td>
<td>0.67 ± 0.03as</td>
</tr>
<tr>
<td>25 kPa</td>
<td>5.5 ± 1.3a</td>
<td>1.3 ± 0.08bs</td>
</tr>
<tr>
<td>75 kPa</td>
<td>11.9 ± 0.39b</td>
<td>1.8 ± 0.08‡</td>
</tr>
<tr>
<td>TCP (&gt;1 GPa)</td>
<td>1.0</td>
<td>0.95 ± 0.03</td>
</tr>
</tbody>
</table>

Relative quantification of mean ± SEM SPARC and myocilin mRNA for the HTM 211, 424, and 431 cells when grown on 5, 25, or 75 kPa hydrogels or TCP under control conditions (DMSO) or with 2 μM Lat-B. For each variable, different superscript letters mean significant effect between hydrogels (\( P < 0.05 \)).

* Statistically significant difference from the SPARC or myocilin mRNA following DMSO or Lat-B treatment (\( P < 0.05 \)).

† Statistically significant difference from the SPARC or myocilin mRNA on a hydrogel versus TCP (\( P < 0.05 \)).

SPARC and myocilin mRNA was significantly increased on the 75 kPa hydrogels in comparison with TCP for all three donors. Even in the least responsive HTM cells (HTM 211) from a 21-year old donor, the 75 kPa hydrogel resulted in a 2.7- and 11.9-fold increase in SPARC and myocilin mRNA in comparison with TCP, respectively. In contrast, SPARC and myocilin mRNA was significantly lower on the 5 kPa hydrogels in comparison with TCP in two of three donors and all three donors, respectively. In addition, SPARC and myocilin mRNA on the 5 kPa hydrogels was significantly less than the 75 kPa hydrogels for all three donors. SPARC and myocilin mRNA on the 25 kPa hydrogels was typically intermediate between the 5 and 75 kPa hydrogels. To ensure that vehicle (DMSO) treatment did not have an appreciable effect on the SPARC and myocilin mRNA expression, HTM cells were treated with an equal volume of DMSO Lat-B. For each variable, different superscript letters mean significant effect between hydrogels (\( P < 0.05 \)).

**Figure 1.** Substratum stiffness impacts SPARC mRNA and cellular response to Lat-B treatment in HTM cells. Cells grown on stiff hydrogels and treated with DMSO had significantly different SPARC mRNA expression in comparison with DMSO-treated cells on TCP (>1 GPa) or more compliant hydrogels. Cells grown on hydrogels and treated with Lat-B had significantly less SPARC mRNA expression versus treatment with DMSO. In contrast, cells grown on TCP and treated with Lat-B had significantly greater SPARC mRNA expression versus treatment with DMSO. Data are mean ± SEM for HTM 424 donor. (\( * P < 0.05 \) for hydrogel versus TCP; \( ^a,b,P < 0.05 \) between the different hydrogels; \( ^†P < 0.05 \) for DMSO versus Lat-B).

**Figure 2.** Substratum stiffness impacts myocilin mRNA and cellular response to Lat-B treatment in HTM cells. Cells grown on stiff hydrogels and treated with DMSO had significantly different myocilin mRNA expression in comparison with DMSO-treated cells on TCP (>1 GPa) or more compliant hydrogels. Cells grown on hydrogels and treated with Lat-B had significantly less myocilin mRNA expression versus treatment with DMSO. In contrast, cells grown on TCP and treated with Lat-B had no significant difference in myocilin mRNA expression versus treatment with DMSO. Data are mean ± SEM for HTM 211 donor. (\( * P < 0.05 \) for hydrogel versus TCP; \( ^a, b, P < 0.05 \) between the different hydrogels; \( ^†P < 0.05 \) for DMSO versus Lat-B).
DPBS and results did not differ significantly between the two groups (data not shown).

After treatment with Lat-B, cells on 75 kPa hydrogels produced significantly less SPARC and myocilin mRNA ($P < 0.05$) in all three donors’ cells (Table 1). In contrast, HTM cells cultured on TCP did not appreciably modulate their expression of SPARC and myocilin in response to Lat-B treatment. HTM cellular response to Lat-B was less marked on the 5 and 25 kPa hydrogels in comparison with the 75 kPa hydrogels. As previously reported, variations in response of HTM cells from different donors can occur and this is observed in the present study of SPARC and myocilin with cells from three donors (HTM 211, 424, and 431) that were aged 21, 42, and 43 years, respectively. While there were variations in the magnitude of SPARC and myocilin expression between the three donors, trends were similar with regard to effects of substratum stiffness and treatment with Lat-B.

Because the response of the cells to Lat-B was so different between the 75 kPa hydrogels that mimic glaucomatous HTM and TCP, we investigated protein expression in the HTM cells under these two conditions. Consistent with the mRNA data, SPARC protein expression was markedly increased on 75 kPa hydrogels in comparison with TCP while Lat-B decreased SPARC protein expression on 75 kPa hydrogels (Fig. 3). Myocilin protein expression was also markedly increased on 75 kPa hydrogels in comparison with TCP (Fig. 4). However, Lat-B did not dramatically alter the amount or distribution of myocilin protein expression within the HTM cells on 75 kPa hydrogels.

**Substratum Stiffness Alters ANGPTL-7, Fibronectin, and TGM-2 Gene Expression**

Substratum stiffness significantly altered the relative amount of fibronectin and TGM-2 mRNA. There was much lower variation in gene expression for ANGPTL-7, fibronectin, and TGM-2 in comparison with SPARC and myocilin between HTM donors. There was a trend toward cells grown on the stiffer hydrogels (75 kPa) and treated with DMSO having less ANGPTL-7 mRNA expression in comparison with DMSO-treated cells on TCP opposite to the results obtained with SPARC and myocilin. Cells grown on 25 and 75 kPa hydrogels and treated with Lat-B also tended to have less ANGPTL-7 mRNA expression in comparison with cells treated with Lat-B on TCP (Fig. 5).

Cells grown on 5 kPa hydrogels had significantly less TGM-2 mRNA expression in comparison with TCP (Fig. 6). Cells grown on 25 kPa hydrogels had significantly less fibronectin
mRNA expression in comparison with TCP (Fig. 7). In addition, treatment with 2 μM Lat-B significantly increased fibronectin mRNA expression on TCP.

**DISCUSSION**

In primary open-angle glaucoma (POAG), increased resistance to AH outflow through the HTM results in elevated IOP. In the normal HTM, there is a dynamic balance between ECM protein production and degradation. Expression of many ECM genes are relatively high within the HTM. ECM turnover is a primary mechanism by which resistance may be altered within the HTM. In POAG, there is an accumulation of cross-linked ECM proteins in the HTM that likely contributes to increased outflow resistance and elevated IOP. A recent study demonstrated that the elastic modulus of HTM increases with glaucoma which could increase the resistance to outflow.

SPARC is a matricellular protein that is widely expressed in ocular tissues including the HTM. The expression of SPARC is significantly increased in the iris with primary angle closure glaucoma (PACC), and SPARC-null mice exhibit significantly lower IOPs suggesting that SPARC is important in outflow resistance. As a matricellular glycoprotein, SPARC is essential in ECM remodeling and has been implicated in disease states especially tissue fibrosis. Mechanical stretching, a mechanism by which HTM cells respond to changes in IOP, also upregulates SPARC expression in HTM cells. Our results show substratum stiffness markedly altered SPARC mRNA and protein expression in HTM cells. Specifically, SPARC mRNA expression was dramatically increased on substrates mimicking the glaucomatous HTM and decreased on substrates mimicking the normal HTM in comparison with rigid TCP. Cells in vivo never interact with matrices possessing stiffness values that approximate TCP (>1 GPa). Culturing HTM cells on hydrogels represents an advantageous method to more closely determine the expression of proteins and cellular behaviors that define cells in tissues.

Myocilin is a secreted glycoprotein for which a consensus has not been reached as to its function. Myocilin is mutated in some forms of POAG with certain mutations associated with more severe phenotypes. SPARC and myocilin have been shown to interact together through their C-terminal domains and proteolytic processing of myocilin modulates its interaction with SPARC which may explain the similarities in expression between SPARC and myocilin in the present study. It has been previously demonstrated that myocilin expression is upregulated with glaucoma. Cells on hydrogels mimicking the stiffness of the glaucomatous HTM also markedly increased the mRNA and protein expression of myocilin, and is more consistent with in vivo conditions than are cells cultured on TCP.

The findings from this study also show that ANGPTL-7 expression tended to decrease on substrates that imitate the glaucomatous HTM. ANGPTL-7 belongs to a family of proteins that are structurally related to the angiopoietins and plays an important role in ECM turnover. It has been shown that ANGPTL-7 is moderately expressed in the HTM and is dramatically upregulated in HTM cells after dexamethasone treatment. Overexpression of ANGPTL-7 in HTM cells decreased the expression of multiple ECM proteins including myocilin and fibronectin and silencing ANGPTL-7 during dexamethasone treatment altered the expression of several steroid-induced proteins. These findings suggest that ANGPTL-7 is important in modulating the HTM ECM and its response to glucocorticoids. Interestingly, ANGPTL-7 mRNA was decreased by 2.5-fold on the stiffest hydrogel (75 kPa) in comparison with TCP and this altered ANGPTL-7 expression may have contributed to the upregulation of myocilin that was observed in this study. Utilization of the 75 kPa hydrogels may represent an alternative to ANGPTL-7 silencing RNA when investigating this protein’s role in glaucoma progression and treatment.

In the present study, TGM-2 expression was significantly decreased on hydrogels that mimic the normal HTM (5 kPa). TGM-2 belongs to a family of calcium-dependent enzymes that are important in posttranslational modification of the ECM via protein cross-linkage. HTM cells from glaucomatous donors showed significantly greater TGM-2 protein expression and enzyme activity. In addition, there was increased colocalization of fibronectin and cross-linked ε-(γ-glutamyl) lysine proteins in glaucomatous donors suggesting that TGM-2 may be instrumental in altering ECM degradation by cross-linking ECM proteins. Similar to TGM-2, fibronectin expression is increased in the HTM with aging, POAG, and in steroid-responsive glaucoma. In the present study, substrate stiffness also affected fibronectin expression after Lat-B treatment.

In addition to investigating the effects of substratum stiffness, this study also demonstrated that Lat-B treatment of HTM cells dramatically decreased SPARC mRNA and protein expression on TCP.
sion and myocilin mRNA expression on hydrogels imitating the stiffness of the glaucomatous HTM but had a much different effect on cells cultured on TCP. However myocilin protein expression was relatively unchanged on the 75 kPa hydrogels after Lat-B treatment which is not surprising given that there is variable correlation between mRNA and protein expression.40 Lat-B in combination with substrate stiffness also had effects on expression of fibronectin and ANGPTL-7 but not TGM-2 in HTM cells. To the authors’ knowledge, this is the first investigation of the effects of Lat-B on the ECM of HTM cells but it has been reported that cytoskeletal disruption of chondrocytes with latrunculin A caused ECM uncoupling and structural changes.50 Lat-B modulation of the ECM may represent an additional mechanism by which this cytoskeletal disruptor decreases resistance to aqueous humor outflow within the HTM and thus lowers IOP. Given that Lat-B is currently in clinical trials as a novel glaucoma therapy, further investigations are warranted to determine the effects of Lat-B and other cytoskeletal disruptors on the structure and composition of the ECM. These studies could provide new insights into the mechanisms by which HTM cells regulate ECM turnover and outflow resistance.

Recently, it was demonstrated that substrate stiffness altered the HTM cellular response to Lat-B with regard to cell morphology and elastic modulus.2 Lat-B treatment of HTM cells on stiff substrates caused dramatic alterations in morphology and elastic modulus while on more compliant substrates Lat-B caused minimal effects in these two variables.2 These observations are consistent with findings in the present study which demonstrate Lat-B treatment to have a minimal effect on SPARC and myocilin expression on hydrogels possessing values for stiffness that mimic the normal HTM.

In conclusion, substrate stiffness had a profound influence on HTM cell expression of ECM proteins that are associated with glaucoma in humans. We also demonstrated that substrate stiffness modulated the response of HTM cells to treatment with Lat-B with regard to expression of these ECM proteins. There is increasing evidence that biophysical cues such as nano- to microscale topography, mechanical stretch, and substrate stiffness profoundly alter HTM cell behaviors and their response to therapeutic agents.6–8,15 The inclusion of biomimetic biophysical attributes of the substratum in vitro is necessary to better reflect many HTM cell behaviors observed in normal and glaucomatous tissue in vivo. By integrating biomimetic biophysical cues as well as soluble signaling factors, the predictive value of in vitro systems will likely increase and accelerate our understanding of glaucoma initiation and progression as well as the development of novel glaucoma therapeutics.

Acknowledgments

The authors thank Marion E. Fischer and Marissa L. Hughbanks for hydrogel production.

References


